Concomitant asthma medication use in patients receiving omalizumab: Results from three large insurance claims databases

Journal of Asthma

Volumn 48, Issue 9, 2011, Pages 923-930

  Lafeuille, Marie Hélne ^a   Duh, Mei Sheng ^b   Zhang, Jie ^c   Wertz, Debra ^d   Gu, Tao ^d   Swensen, Andrine ^c   Lefebvre, Patrick ^a  

^a GROUPE D ANALYSE   (Canada)

^b ANALYSIS GROUP   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d HEALTHCORE INC   (United States)

Author keywords

Allergic asthma; Control; Corticosteroids; Medical charts

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE; MOMETASONE FUROATE; NEDOCROMIL; OMALIZUMAB; TRIAMCINOLONE;

ADULT; ARTICLE; ASTHMA; CORTICOSTEROID THERAPY; DATA BASE; EMERGENCY WARD; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; INSURANCE, HEALTH; MALE; POLYPHARMACY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 80054894204     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2011.618568     Document Type: Article

References (11)

1. Pleis JR, Lucas JW, Ward BW. Summary health statistics for U.S. adults: National Health Interview Survey, 2008. National Cancer for Health Statistics Vital Health Stat 10(242). 2009
2. Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Center for Health Statistics. Vital Health Stat 10(244). 2009
3. Centers for Disease Control and Prevention. MMWR Surveillance Summaries: Surveillance for Asthma, United States: 1980-2004. MMWR 2007; 56(SS-8):1-60
4. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Update 2010. Available at: www.ginasthma.org. [accessed Sept 21 2011]
5. National Asthma Education and Prevention Program. Expert Panel Report 3:Guidelines for the Diagnosis and Management of Asthma. NIH Publication: 08-5846. Bethesda MD: National Institutes of Health, 2007
6. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108(2): 184-190
7. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006; 354(25):2689-2695
8. Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology. Risk/Benefit of omalizumab, 2009. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Pulmonary- AllergyDrugsAdvisoryCommittee/UCM190449.pdf. [accessed Sept 21 2011]
9. Xolair (omalizumab) Prescribing Information. South San Francisco, CA: Genentech, Inc. and Novartis Pharmaceuticals Corporation, East Hanover 2010. Available at: http://www.gene.com/gene/products/ information/pdf/xolair- prescribing.pdf [accessed Sept 21 2011]
10. Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S. Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med 2006; 48(8):794-802
11. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham I. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med. 2009; 103(11):1633-1642